Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shionogi & Co ( (JP:4507) ) has provided an update.
GSK, Pfizer and Shionogi have agreed to restructure their holdings in HIV-focused ViiV Healthcare, with Shionogi replacing Pfizer’s 11.7% economic interest and increasing its own stake to 21.7%, while GSK retains a 78.3% majority position. Under the deal, ViiV will issue new shares to Shionogi for $2.125 billion, cancel Pfizer’s stake, and pay $1.875 billion to Pfizer and a $250 million special dividend to GSK, simplifying ViiV’s shareholder structure and reinforcing Shionogi’s strategic role in advancing ViiV’s long-acting injectable HIV treatments and prevention portfolio, subject to regulatory approvals expected to be completed in the first quarter of 2026.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2700.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a leading global research‑driven pharmaceutical company headquartered in Osaka, Japan, focused on discovering and developing medicines for infectious diseases such as HIV and influenza, as well as treatments for central nervous system disorders. The company has played a key role in the development of innovative HIV integrase inhibitors, including dolutegravir and cabotegravir, and contributes to the pipeline of ViiV Healthcare, a specialist HIV pharmaceutical company in which it is a shareholder.
Average Trading Volume: 2,749,967
Technical Sentiment Signal: Buy
Current Market Cap: Yen2517.7B
Learn more about 4507 stock on TipRanks’ Stock Analysis page.